Amphastar Pharmaceuticals Inc (AMPH)
ROA
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 137 545 | 135 291 | 101 943 | 93 165 | 91 386 | 77 233 | 90 907 | 81 328 |
| Aktywa razem | w tys. USD | 1 512 910 | 1 544 630 | 1 378 270 | 773 656 | 741 987 | 726 695 | 723 719 | 716 238 |
| ROA | 9,09% | 8,76% | 7,40% | 12,04% | 12,32% | 10,63% | 12,56% | 11,35% |
2023/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $137 545K ÷ $1 512 910K
= 9,09%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROA
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Arcus Biosciences Inc
RCUS
-28,04%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Dynavax Technologies Corp.
DVAX
-0,64%
Harmony Biosciences Holdings Inc
HRMY
15,88%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Ligand Pharmaceuticals, Inc.
LGND
6,63%
Myriad Genetics, Inc.
MYGN
-22,97%
Pacira BioSciences Inc
PCRX
2,66%
Supernus Pharmaceuticals Inc
SUPN
0,10%
Xencor Inc
XNCR
-13,23%